Many companies knowingly use inefficient spray-dried formulations to quickly enter Phase 1 trials, deferring major manufacturing and volumetric challenges until later development stages. This "good enough for now" approach often necessitates a complete, costly reformulation later on.

The threat from compounding pharmacies goes beyond patent workarounds. By offering drugs like tirzepatide in custom formulations, they enable flexible microdosing that can reduce side effects and improve patient outcomes. This model of personalization directly challenges the standardized, one-size-fits-all approach of mass-produced pharmaceuticals.

Spray drying requires post-processing like secondary drying and roller compaction. These steps necessitate adding external excipients, leading to two distinct dilution phases that increase final tablet size and patient pill burden, a frequently overlooked drawback compared to denser technologies.

For early-stage biotech companies, saving money by limiting initial drug substance characterization is a false economy. A comprehensive, state-of-the-art characterization before Phase 1 is essential to de-risk the program by identifying molecular issues before they become catastrophic problems in late-stage development.

Pharma teams often fear changing formulations late in development due to perceived regulatory hurdles. However, the path, which involves a relative bioavailability study to bridge the old and new formulations, is a well-established and manageable process if key safety and efficacy metrics are maintained.

A key trend in 2025's drug approvals is that "best-in-class" therapies are distinguished not just by efficacy, but by innovations in formulation and delivery that improve the patient experience. Examples include subcutaneous versions of IV drugs and new delivery methods that expand patient access.

For its oral obesity drug Foundeo, Eli Lilly gained approval for a 17mg tablet, despite pivotal trials using a 35mg capsule. The company used a bioequivalence study to justify the switch, a strategic move that halves the amount of active ingredient needed, preemptively addressing massive supply chain challenges.

Current tools excel at the static binding problem. To advance to creating true therapeutics, models must incorporate the physics of displacing solvent and ions from an interface—currently neglected but one of the "biggest enemies" of strong binding in a physiological context.

Standard glutathione supplements are largely a waste of money because the body lacks a transporter to get it inside cells. To be effective, the supplement must be in a "liposomal" form, which encapsulates the molecule so it can fuse with the cell and be utilized.